Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Kimmel Cancer Center at Jefferson, Philadelphia

Duke University Medical Center, Durham

Carolinas Hematology-Oncology Associates, Charlotte

Atlanta VAMC, Decatur

Winship Cancer Institute, Atlanta

Univeristy of Florida Shands Cancer Center, Gainesville

Sylvester Comprehensive Cancer Center, Miami

U of Alambama at Birmingham Comprehensive Cancer Center, Birmingham

Vanderbilt University-Clinical Trials Center, Nashville

University of Wisconsin Comprehensive Cancer Center, Madison

St. Louis University Health Sciences Center, St Louis

Washington University, Barnard Cancer Center, St Louis

DBA Kansas City Cancer Centers, Kansas City

University of Texas MD Anderson Cancer Center, Houston

University of Colorado Health Sciences Center, Aurora

Hunstman Cancer Institute-University of Utah, Salt Lake City

Cedars-Sinai Comprehensive Cancer Center, Los Angeles

UCLA Medical Center Thoracic Malignancy, Los Angeles

Yale University School Of Medicine, New Haven

Mass. General Hospital Hem/Onc. Associates, Boston